Concept
Dynamic Ctdna
Future of Cancer Science | AACR Cancer Progress Report 2025 / Monitoring Treatment Response and Predicting Resistance
"Monitoring dynamic ctDNA changes during treatment can signal emerging resistance or treatment success. In non–small cell lung cancer, early disappearance of detectable KRAS G12C ctDNA following treatment with sotorasib—a targeted therapy that blocks the KRAS G12C protein—was linked to better outcomes, while persistent ctDNA predicted poor response (88)Skoulidis F, et al. (2025) Nat Med.. In another study, a greater than two-fold drop in ctDNA after one chemotherapy cycle was indicative of sensitivity to platinum-based treatment in small cell lung cancer and was associated with longer survival (1083)Murciano-Goroff YR, et al. (2024) JCO Precis Oncol, 8: e2400216.."
Related Ideas
- Kidney MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Recurrence MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- MRD DetectionFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Clinical BarriersFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Risk StratificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Early DiagnosisFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Treatment ResponseFuture of Cancer Science | AACR Cancer Progress Report 2025 · Enhancing Clinical Decision-Making
- BiomarkersFuture of Cancer Science | AACR Cancer Progress Report 2025 · Improving Detection and Diagnosis